Form 8-K - Current report:
SEC Accession No. 0001641172-25-019892
Filing Date
2025-07-16
Accepted
2025-07-16 16:15:57
Documents
19
Period of Report
2025-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 54410
2 EX-1.1 ex1-1.htm EX-1.1 397320
3 EX-4.1 ex4-1.htm EX-4.1 110028
4 EX-4.2 ex4-2.htm EX-4.2 106247
5 EX-99.1 ex99-1.htm EX-99.1 12496
6 EX-99.2 ex99-2.htm EX-99.2 12801
7 GRAPHIC ex99-2_001.jpg GRAPHIC 15846
  Complete submission text file 0001641172-25-019892.txt   1082677

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE bctx-20250715.xsd EX-101.SCH 3863
9 XBRL DEFINITION FILE bctx-20250715_def.xml EX-101.DEF 26836
10 XBRL LABEL FILE bctx-20250715_lab.xml EX-101.LAB 38188
11 XBRL PRESENTATION FILE bctx-20250715_pre.xml EX-101.PRE 25516
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6537
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 251127632
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)